REMARKS

Claims 1-15 have been cancelled, and new claims have been introduced to show division of the generic structures present in particular claims into groups as identified by the Examiner. In particular, selections of the values of X, Y, Z and n have been used to delineate the allegedly separate inventions. Explicit support for these claim divisions is present in applicants' specification as filed. For example, support for "n is selected to form a five-, seven- or nine-membered ring" is found in: the recitation of numerous homopiperazinyl compounds in the specification (see, for example, Compound Nos. 55-58), the presentation of various ring C structures in, for example, claim 2 as filed, and on pages 7-9. No new matter is introduced thereby.

Restriction Requirement

Applicants have cancelled claims which were deemed by the Examiner as bridging the groups of invention determined to exist in the instant application. In their place, applicants have written new claims which divide the genus claims into the groups identified by the Examiner. Thus, new claims 25-39 (as well as originally filed claims 16-24) are believed to fall within Group I (drawn to compounds where ring C is piperazine, i.e., where X is N and n is 1).

Applicants, without traverse, hereby select Group I for further prosecution at this time.

All Applicants rights are reserved with respect to prosecution of the subject matter of non-elected groups.

CONCLUSION

In light of the foregoing, Applicants believe this application should be examined promptly, and respectfully request the Examiner to pass the same to issuance. Authorization is hereby given to charge any fees deemed to be due in connection herewith to Deposit Account No. 50-0912.

Respectfully submitted,

MEHTA et al.

George E. Heibe

Reg. No. 42,648

Dated: September 4, 2003

Correspondence Address:

Ranbaxy Pharmaceuticals Inc. 600 College Road East, Suite 2100 Princeton, New Jersey 08540

Telephone: (609) 720-5334 Facsimile: (609) 514-9779